Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Voyageur Secures First International Sales Contract worth US$1.9 Million (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Athersys Inc ATHXQ

Healthcare Biotechnology
Athersys, Inc. is a biotechnology company focused primarily on the field of regenerative medicine. The Company is engaged in the discovery and development of therapeutic product candidates to address unmet medical needs in multiple disease areas. Its MultiStem (invimestrocel) cell therapy, which is an allogeneic stem cell product candidate, is its lead platform product and is in late-stage... see more

Recent & Breaking News (PINL:ATHXQ)

Research Reports Initiation on Biotech Stocks -- Radius Health, Acorda, PhaseRx, and Athersys

PR Newswire March 22, 2017

Two New Publications Highlight the Potential for MultiStem® Treatment of Ischemic Stroke

GlobeNewswire March 20, 2017

Athersys Reports Financial Results for Fourth Quarter, Full Year 2016

GlobeNewswire March 9, 2017

Overview of MultiStem® Clinical Trial in Japan Presentation at International Stroke Conference 2017

GlobeNewswire February 23, 2017

Athersys to Host Year-End 2016 Financial Results Call

GlobeNewswire February 14, 2017

Athersys Announces Closing of Public Offering of Common Stock

GlobeNewswire February 1, 2017

Mid-Afternoon Market Update: Celestica Rises On Earnings Beat; KEYW Shares Slide

Benzinga.com  January 27, 2017

Mid-Day Market Update: Crude Oil Down 2%; Stonegate Mortgage Shares Spike Higher

Benzinga.com  January 27, 2017

Mid-Morning Market Update: Markets Mostly Flat; Alphabet Profit Misses Views

Benzinga.com  January 27, 2017

Athersys Announces Pricing of Public Offering of Common Stock

GlobeNewswire January 27, 2017

Athersys Announces Proposed Public Offering of Common Stock

GlobeNewswire January 26, 2017

Athersys Subsidiary and Leading Animal Health Company Enter Into Research and Option Agreement for Cell Therapy

GlobeNewswire January 18, 2017

Athersys Reports Third Quarter 2016 Results

GlobeNewswire November 9, 2016

Athersys to Present at Stifel 2016 Healthcare Conference in New York

GlobeNewswire November 3, 2016

Athersys to Host Third Quarter Financial Results Call

GlobeNewswire October 11, 2016

Athersys Receives FDA Agreement Under Special Protocol Assessment for Phase 3 Study of MultiStem® Treatment for Ischemic Stroke

GlobeNewswire September 28, 2016

Athersys Announces Acceptance by PMDA of Clinical Trial Notification in Japan for Treatment of Ischemic Stroke With MultiStem®

GlobeNewswire September 12, 2016

Athersys Reports Second Quarter 2016 Results

GlobeNewswire August 9, 2016

Athersys to Host Second Quarter Financial Results Call

GlobeNewswire July 7, 2016

Pre-Market Review on Biotechnology Equities -- Northwest Biotherapeutics, Titan Pharma, Ultragenyx Pharma, and Athersys

PR Newswire June 29, 2016